Antibiotic resistance and modern strategy of antibacterial therapy

Antibiotic resistance is a serious health problem. The use of new dosage forms of antibiotics should comply with the strategy of rational use of antimicrobials, which includes a set of measures for hospitals and outpatient network aimed at preserving the effectiveness of existing antibiotics. The principles of the strategy for the use of antimicrobial/antibacterial drugs: the exclusion of unjustified prescribing of antibiotics, the priority of prescribing drugs based on the identification of the bacterial agent and its sensitivity to the antibiotic in comparison with empirical prescribing, taking into account data on regional antibiotic resistance, the application of the principle of minimum sufficiency in relation to the choice of the drug – its dose, the choice of route of administration, safety and duration of treatment. The article uses the example of healthcare systems in different countries to assess the effectiveness of the strategy of rational use of antimicrobials. The problem of unjustified use of antibiotics in the treatment of COVID-19 is discussed. New innovative forms of antibiotics are dispersible tablets. Amoxicillin EXPRESS and Amoxicillin + Clavulanic Acid EXPRESS are antibiotics with improved pharmacokinetic properties in the form of dispersible tablets that have proven their safety and effectiveness against many gram-positive and gram-negative microorganisms. The analysis of the effectiveness of therapy of diseases caused by beta-hemolytic streptococcus group A, with the use of two forms: Amoxicillin and Amoxicillin + Clavulanic acid. A clinical case of the use of Amoxicillin + Clavulanic acid EXPRESS in the form of dispersible tablets is presented, which confirms the effectiveness of this drug in the treatment of acute streptococcal tonsillitis.

1. Hargreaves S., Nellums L. (eds.) Global Antimicrobial Resistance Surveillance System (GLASS) Report. Switzerland: World Health Organization; 2018. 268 p. Available at: https://www.who.int/docs/default-source/searo/amr/global-antimicrobial-resistance-surveillance-system---glass-report-early-implementation-2017-2018.pdf?sfvrsn=7e629fec_6.

2. Bell B., Bell M., Bowen A., Braden C., Brandt M., Brown A. et al. Antibiotic Resistance Threats in the United States, 2013. Washington: U.S. Department of Health and Human Services; 2013. 114 p. Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.

3. Burnham J.P., Olsen M.A., Kollef M.H. Re-estimating annual deaths due to multidrug- resistant organism infections. Infect Control Hosp Epidemiol. 2019;40(1):112–113. http://doi.org/10.1017/ice.2018.304.

4. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. UK; 2014. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.

5. Barlam T.F., Cosgrove S.E., Abbo L.M., MacDougall C., Schuetz A.N., Septimus E.J. et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–e77. http://doi.org/10.1093/cid/ciw118.

6. Teshome B.F., Vouri S.M., Hampton N., Kollef M.H., Micek S.T. Duration of exposure to antipseudomonal beta-lactam antibiotics in the critically ill and development of new resistance. Pharmacotherapy. 2019;39(3):261–270. http://doi.org/10.1002/phar.2201.

7. Fernandez-Lazaro C.I., Brown K.A., Langford B.J., Daneman N., Garber G., Schwartz K.L. Late-career Physicians Prescribe Longer Courses of Antibiotics. Clin Infect Dis. 2019;69(9):1467–1475. http://doi.org/10.1093/cid/ciy1130.

8. Dunaway S., Orwig K.W., Arbogast Z.Q., Myers Z.L., Sizemore J.A., Giancola S.E. Evaluation of a pharmacy- driven methicillin-resistant Staphylococcus aureus surveillance protocol in pneumonia. Int J Clin Pharm. 2018;40(3):526–532. http://doi.org/10.1007/s11096-018-0647-3.

9. Cole K.A., Rivard K.R., Dumkow L.E. Antimicrobial Stewardship Interventions to Combat Antibiotic Resistance: An Update on Targeted Strategies. Curr Infect Dis Rep. 2019;21(10):33. http://doi.org/10.1007/s11908-019-0689-2.

10. Demoré B., Tebano G., Gravoulet J., Wilcke C., Ruspini E., Birgé J. et al. Rapid antigen test use for the management of group A streptococcal pharyngitis in community pharmacies. Eur J Clin Microbiol Infect Dis. 2018;37(9):1637–1645. http://doi.org/10.1007/s10096-018-3293-8.

11. Joseph P., Godofsky E. Outpatient Antibiotic Stewardship: A Growing Frontier- Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use. Open Forum Infect Dis. 2018;5(2):ofy024. http://doi.org/10.1093/ofid/ofy024.

12. Keske Ş., Ergönül Ö., Tutucu F., Karaaslan D., Palaoğlu E., Can F. The rapid diagnosis of viral respiratory tract infections and its impact on antimicrobial stewardship programs. Eur J Clin Microbiol Infect Dis. 2018;37(4):779–783. http://doi.org/10.1007/s10096-017-3174-6.

13. Schuetz P., Wirz Y., Sager R., Christ- Crain M., Stolz D., Tamm M. et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498. http://doi.org/10.1002/14651858.CD007498.pub3.

14. Taymaz T., Ergönül Ö., Kebapcı A., Okyay R. Significance of the detection of influenza and other respiratory viruses for antibiotic stewardship: Lessons from the post-pandemic period. Int J Infect Dis. 2018;77:53–56. http://doi.org/10.1016/j.ijid.2018.10.003.

15. Teratani Y., Hagiya H., Koyama T., Ohshima A., Zamami Y., Tatebe Y. et al. Association between rapid antigen detection tests and antibiotics for acute pharyngitis in Japan: A retrospective observational study. J Infect Chemother. 2019;25(4):267–272. http://doi.org/10.1016/j.jiac.2018.12.005.

16. Fralick M., Haj R., Hirpara D., Wong K., Muller M., Matukas L. et al. Can a smartphone app improve medical trainees’ knowledge of antibiotics? Int J Med Educ. 2017;8:416–420. http://doi.org/10.5116/ijme.5a11.8422.

17. Hansen M.J., Carson P.J., Leedahl D.D., Leedahl N.D. Failure of a Best Practice Alert to Reduce Antibiotic Prescribing Rates for Acute Sinusitis Across an Integrated Health System in the Midwest. J Manag Care Spec Pharm. 2018;24(2):154–159. http://doi.org/10.18553/jmcp.2018.24.2.154.

18. Evaluation and diagnosis of penicillin allergy for healthcare professionals. Centers for Disease Control and Prevention, 2017; Available at: https://www.cdc.gov/antibiotic-use/clinicians/Penicillin-Allergy.html

19. Blumenthal K.G., Ryan E.E., Li Y., Lee H., Kuhlen J.L., Shenoy E.S. The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk. Clin Infect Dis. 2018;66(3):329–336. http://doi.org/10.1093/cid/cix794.

20. Kuruvilla M., Shih J., Patel K., Scanlon N. Direct oral amoxicillin challenge without preliminary skin testing in adult patients with allergy and at low risk with reported penicillin allergy. Allergy Asthma Proc. 2019;40(1):57–61. http://doi.org/10.2500/aap.2019.40.4184.

21. Trubiano J.A., Smibert O., Douglas A., Devchand M., Lambros B., Holmes N.E. et al. The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. Open Forum Infect Dis. 2018;5(12):ofy306. http://doi.org/10.1093/ofid/ofy306.

22. Rezel-P otts E., L’Esperance V., Gulliford M.C. Antimicrobial stewardship in the UK during the COVID-19 pandemic: a population-b ased cohort study and interrupted time-series analysis. Br J Gen Pract. 2021;71(706):e331–e338. http://doi.org/10.3399/BJGP.2020.1051.

23. Karami Z., Knoop B.T., Dofferhoff A.S.M., Blaauw M.J.T., Janssen N.A., van Apeldoorn M. et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond). 2021;53(2):102–110. http://doi.org/10.1080/23744235.2020.1839672.

24. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020;71(9):2459–2468. http://doi.org/10.1093/cid/ciaa530.

25. Rothe K., Feihl S., Schneider J., Wallnöfer F., Wurst M., Lukas M. et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2021;40(4):859–869. http://doi.org/10.1007/s10096020-04063-8.

26. Kim D., Quinn J., Pinsky B., Shah N.H., Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA. 2020;323(20):2085–2086. http://doi.org/10.1001/jama.2020.6266.

27. Sticchi C., Alberti M., Artioli S., Assensi M., Baldelli I., Battistini A. et al. Regional point prevalence study of healthcare- associated infections and antimicrobial use in acute care hospitals in Liguria, Italy. J Hosp Infect. 2018;99(1):8–16. http://doi.org/10.1016/j.jhin.2017.12.008.

28. Akram S., Khan M.A., Rehman A., Usman shah H.B., Abbas A. Comparison of Intravenous Co-amoxiclav and Benzyl Penicillin in Children with Severe Streptococcal Tonsillitis. J Islamabad Med Dental College. 2020;9(2):82–87. http://doi.org/10.35787/jimdc.v9i2.489.

29. Huttner A., Bielicki J., Clements M.N., Frimodt- Møller N., Muller A.E., Paccaud J.P, Mouton J.W. Oral amoxicillin and amoxicillin- clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020;26(7):871–879. http://doi.org/10.1016/j.cmi.2019.11.028. Epub 2019 Dec 4. PMID: 31811919.

30. Livermore D.M. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother. 1993;31(Suppl_A):9–21. http://doi.org/10.1093/jac/31.suppl_a.9.

31. Yakovlev S.V., Dovgan E.V. Aspects of Antibiotic Efficacy. Spravochnik Poliklinicheskogo Vracha. 2014;(6):4–5. (In Russ.) Available at: http://antimicrob.net/wp-content/uploads/16_S.V.YAkovlev_E.V.Dovgan_Aspekty_yeffektivnosti_antibiotikov_Spravochnik_poliklinicheskogo_vracha_6_2014.pdf.

32. Yakovlev S.V., Rafalskiy V.V., Sidorenko S.V., Spichak T.V. (eds.). Strategy and tactics for the rational use of antimicrobial agents in outpatient practice: Eurasian practical recommendations. Moscow: Pre100 Print; 2016. 144 p. (In Russ.) Available at: https://webmed.irkutsk.ru/doc/pdf/antib.pdf.

33. Svistushkin V.M., Mustafaev D.M. The problem of antibacterial resistance in infections of ENT organs: is a solution possible? RMJ. 2016;(4):212–216. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Problema_antibakterialynoy_rezistentnosti_pri_infekciyah_LOR-organov_vozmoghno_li_reshenie.

34. Moczarnik J., Berger D.J., Noxon J.O., LeVine D.N., Lin Z., Coetzee J.F., Mochel J.P. Relative Oral Bioavailability of Two Amoxicillin- Clavulanic Acid Formulations in Healthy Dogs: A Pilot Study. J Am Anim Hosp Assoc. 2019;55(1):14–22. http://doi.org/10.5326/JAAHA-MS-6872.

35. Karpov O.I. Flemoklav solutab – a new dosage form of amoxicillin / clavulanate in the treatment of sinusitis. Clinical Pharmacology and Therapy. 2006;15(4):74–77. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9312869.

36. Guchev I.A., Kozlov R.S. Safety and efficacy of different drug forms of amoxicillin/clavulanic acid in treatment of lower respiratory tract infections in adults: an open prospective randomized trial. Pulmonologiya. 2008;(2):73–80. (In Russ.) Available at: https://elibrary.ru/item. asp?id=11571138.

37. Yakovlev S.V. Rational use of antibiotics in outpatient practice. Moscow: Farmprosvet; 2017. 108 p. (In Russ.) Available at: http://antimicrob.net/wp-content/uploads/Alliance_workbook_2017c.pdf.

38. Zyryanov S.K., Baibulatova E.A. The Use of New Dosage Forms of Antibiotics as a Way to Improve the Effectiveness and Safety of Antibiotic Therapy. Antibiotiki i Khimioterapiya. 2019;64(3–4):81–91. (In Russ.) http://doi.org/10.24411/0235-2990-2019-10020.

39. Girina A.A., Karpova E.P., Tulupov D.A., Lepiseva I.V., Zaplatnikov A.L. Acute bacterial infections of the upper respiratory tract: principles of starting etiotropic therapy (agreed position of pediatricians and otorhinolaryngologists). Lechaschi Vrach. 2022;1(25):30–34. (In Russ.) http://doi. org/10.51793/OS.2022.25.1.005.

40. Daykhes N.A., Baranova A.A., Lobzin Yu.V., Namazova-Baranova L.S., Kozlov R.S., Polyakov D.P. Acute tonsillitis and pharyngitis (Acute tonsillopharyngitis): clinical guidelines. Moscow; 2021. (In Russ.) Available at: https://www.garant.ru/products/ipo/prime/doc/402776263/.

41. Rothrock S.G., Green S.M., Harper M.B., Clark M.C., McIlmail D.P., Bachur R. Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis. Acad Emerg Med. 1998;5(6):599–606. http://doi. org/10.1111/j.1553-2712.1998.tb02468.x.

42. Rimoin A.W., Hoff N.A., Fischer Walker C.L., Hamza H.S., Vince A., Rahman N.A. et al. Treatment of streptococcal pharyngitis with once-daily amoxicillin versus intramuscular benzathine penicillin G in low-resource settings: a randomized controlled trial. Clin Pediatr (Phila). 2011;50(6):535–542. http://doi.org/10.1177/0009922810394838.

43. Pocket book of hospital care for children. 2nd ed. Geneva: World Health Organization; 2013. Available at: https://www.ncbi.nlm.nih.gov/books/NBK154447.